Cite

HARVARD Citation

    Kammüller, M. et al. (2017). Inhibition of IL‐17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Clinical & translational immunology. 6 (8), p. n/a. [Online]. 
  
Back to record